The Trump administration wants to rewrite FDA rules so that virtually any man with low testosterone and a flagging libido can qualify for hormone therapy, regardless of why his levels are low. Influential voices from Joe Rogan to Health Secretary RFK Jr. are publicly broadcasting their own testosterone use. And a booming industry of online clinics is already handing out prescriptions like Halloween candy. What could go wrong?
The 'Low T' Gold Rush Is Already Here
Before the Trump administration even touches a single FDA regulation, the testosterone market is already a wild west. As NPR reports, social media is swamped with content about 'low T' panic and 'T-maxxing' tutorials, and a sprawling ecosystem of online clinics has made getting a testosterone prescription roughly as complicated as ordering a pizza.
Dr. Jamin Brahmbhatt, a urologist at Orlando Health in Florida, told NPR he sees men who have spent hours in Reddit forums convincing themselves they need testosterone therapy before they've spoken to a single doctor or had a single blood test. He has some sympathy for them. He also, at various points, suspected he himself might have low testosterone. Turned out he was sleeping badly and stressed out. Completely normal levels.
'Not every guy needs to be on it,' Brahmbhatt told NPR. That sentence is doing a lot of heavy lifting right now.
What the FDA Currently Says, and What the Administration Wants to Change
Here is the existing rule, stated plainly: the FDA currently only approves testosterone therapy for men whose low levels can be traced to a specific, identifiable medical condition. We're talking rare genetic disorders, pituitary dysfunction, that kind of thing. The label explicitly states that the safety and effectiveness of testosterone for age-related hormone decline has not been established.
The Trump administration wants to remove that language. According to NPR, the administration has signaled it wants to expand eligibility so that any man with low testosterone, whatever the cause, can qualify for treatment as long as he has low libido as a symptom. Age-related decline, lifestyle factors, the general entropy of middle age — all of it would be enough to get on the prescription train.
The administration has also drawn attention from people like Dr. Martin Miner, who co-directs the Men's Health Center at the Miriam Hospital in Providence and serves as president of the Androgen Society, and who has consulted for companies that make testosterone. He wants testosterone moved out of its current controlled-substance category, where it sits alongside drugs like ketamine. He told NPR the current restrictions are 'long overdue' for revision. He used a blood pressure analogy: you treat the condition, not the cause. His financial ties to the testosterone industry are, at minimum, worth knowing about when weighing that argument.
The Doctors Who Are Not Excited About This
Dr. Steven Woloshin, a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice, told NPR flatly: 'I think it is too soon. I think we really need to have a better handle on the long-term benefits and harms.' Woloshin has previously testified in court against a testosterone manufacturer, which gives him a different kind of financial-conflict disclosure than Miner.
Dr. Helen Bernie, director of Sexual and Reproductive Medicine at Indiana University, is worried about something else: the complete disconnect between what testosterone therapy is actually for and what the online clinic industry and the influencer complex are selling. 'The goal of testosterone therapy isn't peak performance,' she told NPR. 'It's not some drug to promise the fountain of youth. It is restoring normal physiology in men who have a true deficiency.' She described the gap between marketing and medicine as something that really needs separating out.
That gap is currently the size of the Grand Canyon. And the administration's regulatory changes would make it considerably wider.
The Symptoms Problem Nobody Wants to Talk About
Here is where the science gets genuinely complicated, and genuinely exploitable. The symptoms of testosterone deficiency, clinically called hypogonadism, include fatigue, depressed mood, reduced libido, weight gain, and trouble concentrating. Sound familiar? They should. They also describe being a stressed-out, sleep-deprived adult human in 2026 trying to keep up with the news.
As NPR reports, doctors point out that low testosterone in younger and middle-aged men is frequently tied to obesity, diabetes, sleep apnea, drug use, and smoking. Fix those things, and the testosterone levels often improve on their own. Brahmbhatt knows this firsthand. He thought he had low T. He needed more sleep.
The problem with loosening the diagnostic criteria is that you make it much easier for symptom lists that describe half the adult male population to translate directly into prescriptions. Online clinics, which NPR reports already skip much of the necessary testing and follow-up, are not going to be the ones pumping the brakes.
The Military Angle That Isn't Getting Enough Attention
While everyone is focused on the online clinic boom and the influencer testosterone discourse, NPR also notes that the military plans to begin screening service members for low testosterone. Just sit with that for a second.
A mandatory screening program, across the entire U.S. military, at the exact moment the administration is trying to expand who qualifies for treatment and relax how testosterone is categorized as a controlled substance. The scale of what that could mean, both for prescribing volume and for long-term health data we don't yet have, is not a small thing.
Testosterone was one of the fastest-growing prescription drugs in the United States during the early 2000s before safety concerns started slowing things down. The administration appears to be eyeing the accelerator again.
The Dingo Take
You are supposed to believe this is about men's health. And some of it genuinely is. Testosterone deficiency is a real medical condition. Men's health has been under-researched and under-discussed for decades, and there is a legitimate conversation to have about whether the FDA's current criteria are too restrictive. Brahmbhatt and Bernie both say as much, carefully, with caveats.
But the Trump administration is not approaching this like a careful medical policy discussion. This is the same administration that has been systematically gutting the FDA's credibility, installing industry-friendly figures across health agencies, and treating 'access' as a political slogan rather than a clinical standard. The loudest voices cheering this on include RFK Jr., who is literally the Health Secretary, a man who has spent his career undermining pharmaceutical and regulatory trust, now enthusiastically promoting a pharmaceutical product. Joe Rogan is not a doctor. These are the faces of this push.
The long-term safety data on testosterone therapy, particularly for men without a classical deficiency, is still thin. Dartmouth's Woloshin said so. The FDA's own label said so. The administration wants to delete the label. The online clinics are already skipping the follow-up testing. And now the military is going to screen every service member. At some point the number of red flags stops being a coincidence and starts being the story.
Comments